
Lei Yao
Examiner (ID: 12775, Phone: (571)272-3112 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1642 |
| Total Applications | 1328 |
| Issued Applications | 662 |
| Pending Applications | 127 |
| Abandoned Applications | 552 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 12227675
[patent_doc_number] => 09914909
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-03-13
[patent_title] => 'Costimulatory chimeric antigen receptor T cells targeting IL13Rα2'
[patent_app_type] => utility
[patent_app_number] => 15/167869
[patent_app_country] => US
[patent_app_date] => 2016-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 42
[patent_figures_cnt] => 62
[patent_no_of_words] => 12669
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15167869
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/167869 | Costimulatory chimeric antigen receptor T cells targeting IL13Rα2 | May 26, 2016 | Issued |
Array
(
[id] => 13125723
[patent_doc_number] => 10080776
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-09-25
[patent_title] => Molecular marker for cancer stem cell
[patent_app_type] => utility
[patent_app_number] => 15/162833
[patent_app_country] => US
[patent_app_date] => 2016-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 34
[patent_no_of_words] => 14837
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15162833
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/162833 | Molecular marker for cancer stem cell | May 23, 2016 | Issued |
Array
(
[id] => 11061998
[patent_doc_number] => 20160258960
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-08
[patent_title] => 'DETECTION OF CANCER BY ELEVATED LEVELS OF BCL-2'
[patent_app_type] => utility
[patent_app_number] => 15/160649
[patent_app_country] => US
[patent_app_date] => 2016-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 21166
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15160649
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/160649 | DETECTION OF CANCER BY ELEVATED LEVELS OF BCL-2 | May 19, 2016 | Abandoned |
Array
(
[id] => 13590035
[patent_doc_number] => 20180346566
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => METHODS AND COMPOSITIONS RELATING TO ANTI-TMIGD1/IGPR-2
[patent_app_type] => utility
[patent_app_number] => 15/572263
[patent_app_country] => US
[patent_app_date] => 2016-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33726
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15572263
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/572263 | METHODS AND COMPOSITIONS RELATING TO ANTI-TMIGD1/IGPR-2 | May 18, 2016 | Abandoned |
Array
(
[id] => 13360027
[patent_doc_number] => 20180231553
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-16
[patent_title] => COMPOSITION FOR ANTICANCER ADJUVANT COMPRISING RIP3 EXPRESSION PROMOTER AS ACTIVE INGREDIENT, METHOD FOR SCREENING ANTICANCER ADJUVANT WHICH PROMOTES RIP3 EXPRESSION AND ENHANCES SENSITIVITY OF ANTICANCER AGENT, AND METHOD FOR MONITORING SENSITIVITY OF ANTICANCER AGENT
[patent_app_type] => utility
[patent_app_number] => 15/750421
[patent_app_country] => US
[patent_app_date] => 2016-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7367
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750421
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/750421 | Composition for anticancer adjuvant comprising RIP3 expression promoter as active ingredient, method for screening anticancer adjuvant which promotes RIP3 expression and enhances sensitivity of anticancer agent, and method for monitoring sensitivity of anticancer agent | May 6, 2016 | Issued |
Array
(
[id] => 11529931
[patent_doc_number] => 20170089909
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-03-30
[patent_title] => 'METHODS AND COMPOSITIONS FOR ASSAYING BLOOD LEVELS OF LEGUMAIN'
[patent_app_type] => utility
[patent_app_number] => 15/146179
[patent_app_country] => US
[patent_app_date] => 2016-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 11653
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15146179
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/146179 | METHODS AND COMPOSITIONS FOR ASSAYING BLOOD LEVELS OF LEGUMAIN | May 3, 2016 | Abandoned |
Array
(
[id] => 16499875
[patent_doc_number] => 10865250
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-12-15
[patent_title] => Anti-cancer fusion polypeptide
[patent_app_type] => utility
[patent_app_number] => 15/571561
[patent_app_country] => US
[patent_app_date] => 2016-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 24
[patent_no_of_words] => 27901
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15571561
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/571561 | Anti-cancer fusion polypeptide | May 3, 2016 | Issued |
Array
(
[id] => 13343653
[patent_doc_number] => 20180223366
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-09
[patent_title] => DIAGNOSTIC, PREDICTIVE AND PROGNOSTIC TESTING FOR CANCER
[patent_app_type] => utility
[patent_app_number] => 15/141908
[patent_app_country] => US
[patent_app_date] => 2016-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16997
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15141908
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/141908 | DIAGNOSTIC, PREDICTIVE AND PROGNOSTIC TESTING FOR CANCER | Apr 28, 2016 | Abandoned |
Array
(
[id] => 12603411
[patent_doc_number] => 20180092967
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-04-05
[patent_title] => IMMUNITY-INDUCING AGENT
[patent_app_type] => utility
[patent_app_number] => 15/567448
[patent_app_country] => US
[patent_app_date] => 2016-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11308
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 145
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15567448
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/567448 | IMMUNITY-INDUCING AGENT | Apr 27, 2016 | Abandoned |
Array
(
[id] => 14808349
[patent_doc_number] => 20190270784
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-05
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 16/305686
[patent_app_country] => US
[patent_app_date] => 2016-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58983
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16305686
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/305686 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers | Apr 21, 2016 | Issued |
Array
(
[id] => 11120710
[patent_doc_number] => 20160317683
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-11-03
[patent_title] => 'Therapeutic Agents and Uses Thereof'
[patent_app_type] => utility
[patent_app_number] => 15/135028
[patent_app_country] => US
[patent_app_date] => 2016-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 46
[patent_no_of_words] => 18999
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15135028
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/135028 | Therapeutic Agents and Uses Thereof | Apr 20, 2016 | Abandoned |
Array
(
[id] => 11023696
[patent_doc_number] => 20160220651
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-08-04
[patent_title] => 'IMMUNOGENIC TUMOR ASSOCIATED STROMAL CELL ANTIGEN PEPTIDES AND METHODS OF THEIR USE'
[patent_app_type] => utility
[patent_app_number] => 15/133038
[patent_app_country] => US
[patent_app_date] => 2016-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 45696
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15133038
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/133038 | Immunogenic tumor associated stromal cell antigen peptides and methods of their use | Apr 18, 2016 | Issued |
Array
(
[id] => 16956051
[patent_doc_number] => 11059893
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-13
[patent_title] => Humanized anti-AXL antibodies
[patent_app_type] => utility
[patent_app_number] => 15/566635
[patent_app_country] => US
[patent_app_date] => 2016-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 2
[patent_no_of_words] => 15379
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15566635
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/566635 | Humanized anti-AXL antibodies | Apr 14, 2016 | Issued |
Array
(
[id] => 11077151
[patent_doc_number] => 20160274114
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-22
[patent_title] => 'METHODS FOR DIAGNOSING CANCER AND DETERMINING THE OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL OF CANCER PATIENTS'
[patent_app_type] => utility
[patent_app_number] => 15/089770
[patent_app_country] => US
[patent_app_date] => 2016-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 11213
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15089770
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/089770 | METHODS FOR DIAGNOSING CANCER AND DETERMINING THE OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL OF CANCER PATIENTS | Apr 3, 2016 | Abandoned |
Array
(
[id] => 12746656
[patent_doc_number] => 20180140719
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-24
[patent_title] => SELF ASSEMBLING MOLECULES FOR TARGETED DRUG DELIVERY
[patent_app_type] => utility
[patent_app_number] => 15/563339
[patent_app_country] => US
[patent_app_date] => 2016-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12769
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15563339
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/563339 | SELF ASSEMBLING MOLECULES FOR TARGETED DRUG DELIVERY | Mar 30, 2016 | Abandoned |
Array
(
[id] => 11094027
[patent_doc_number] => 20160290995
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-10-06
[patent_title] => 'METHODS OF SELECTING AKT AGONISTS OR ANTAGONISTS'
[patent_app_type] => utility
[patent_app_number] => 15/085757
[patent_app_country] => US
[patent_app_date] => 2016-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 47
[patent_figures_cnt] => 47
[patent_no_of_words] => 20458
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15085757
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/085757 | METHODS OF SELECTING AKT AGONISTS OR ANTAGONISTS | Mar 29, 2016 | Abandoned |
Array
(
[id] => 12641301
[patent_doc_number] => 20180105598
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-04-19
[patent_title] => ANTI-CD133 MONOCLONAL ANTIBODIES AND RELATED COMPOSITIONS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 15/561403
[patent_app_country] => US
[patent_app_date] => 2016-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20390
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15561403
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/561403 | Anti-CD133 monoclonal antibodies and related compositions and methods | Mar 27, 2016 | Issued |
Array
(
[id] => 12259404
[patent_doc_number] => 20180078599
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-03-22
[patent_title] => 'METHODS AND MATERIALS FOR TREATING CANCER'
[patent_app_type] => utility
[patent_app_number] => 15/562136
[patent_app_country] => US
[patent_app_date] => 2016-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 37
[patent_figures_cnt] => 37
[patent_no_of_words] => 7904
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15562136
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/562136 | METHODS AND MATERIALS FOR TREATING CANCER | Mar 24, 2016 | Abandoned |
Array
(
[id] => 11401747
[patent_doc_number] => 20170022286
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-01-26
[patent_title] => 'MEDICAL USES OF CRTAM AGONISTS'
[patent_app_type] => utility
[patent_app_number] => 15/078901
[patent_app_country] => US
[patent_app_date] => 2016-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 14472
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15078901
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/078901 | MEDICAL USES OF CRTAM AGONISTS | Mar 22, 2016 | Abandoned |
Array
(
[id] => 11075757
[patent_doc_number] => 20160272721
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-22
[patent_title] => 'ANTIBODY SPECIFIC TO THE AIMP2-DX2'
[patent_app_type] => utility
[patent_app_number] => 15/074498
[patent_app_country] => US
[patent_app_date] => 2016-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 50
[patent_figures_cnt] => 50
[patent_no_of_words] => 29193
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15074498
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/074498 | Antibody specific to the AIMP2-DX2 | Mar 17, 2016 | Issued |